{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:15Z","timestamp":1792723095338,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e01050","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:57:47Z","timestamp":1788951467000},"page":"e01050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Next-generation therapeutics for glioblastoma: Challenges and future directions"],"prefix":"10.1016","volume":"23","author":[{"given":"Juan B.","family":"Blaquier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Lim-Fat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neurot.2026.e01050_bib1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01050_bib2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-020-03451-6","article-title":"Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis","volume":"147","author":"Marenco-Hillembrand","year":"2020","journal-title":"J Neuro Oncol"},{"issue":"Supplement_4","key":"10.1016\/j.neurot.2026.e01050_bib3","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20142020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01050_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01050_bib5","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01050_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01050_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11060-015-1958-z","article-title":"A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients","volume":"126","author":"Raizer","year":"2016","journal-title":"J Neuro Oncol"},{"issue":"23","key":"10.1016\/j.neurot.2026.e01050_bib10","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41698-025-00920-x","article-title":"Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy","volume":"9","author":"Zhao","year":"2025","journal-title":"npj Precis Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01050_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473324","article-title":"Incorporating targeted therapy into neuro-oncology practice","volume":"45","author":"Geurts","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pneurobio.2005.04.006","article-title":"Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases","volume":"76","author":"Loscher","year":"2005","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01050_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2026.e01050_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1067252","article-title":"Implications of BRAF V600E mutation in gliomas: molecular considerations, prognostic value and treatment evolution","volume":"12","author":"Di Nunno","year":"2023","journal-title":"Front Oncol"},{"issue":"6099","key":"10.1016\/j.neurot.2026.e01050_bib16","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01050_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00183","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","author":"Okamura","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01050_bib18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/2159-8290.CD-13-0879","article-title":"EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing","volume":"4","author":"Francis","year":"2014","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01050_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc3918","article-title":"Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma","volume":"15","author":"Furnari","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01050_bib21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-019-03222-y","article-title":"Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma","volume":"144","author":"Lassman","year":"2019","journal-title":"J Neuro Oncol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01050_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s43018-020-00159-4","article-title":"Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities","volume":"2","author":"Garofano","year":"2021","journal-title":"Nat Cancer"},{"issue":"Supplement_5","key":"10.1016\/j.neurot.2026.e01050_bib24","doi-asserted-by":"crossref","first-page":"v46","DOI":"10.1093\/neuonc\/noaf201.0181","article-title":"BIOM-93. Prognostic and predictive implications of BRAF V600 mutations in adult high-grade gliomas","volume":"27","author":"Blaquier","year":"2025","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01050_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/nop\/npaf068","article-title":"Clinical experience with tovorafenib in adults with treatment-refractory high- and low-grade gliomas","volume":"12","author":"Ioannou","year":"2025","journal-title":"Neuro-Oncol Pract"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01050_bib28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1750-3639.2012.00603.x","article-title":"KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults","volume":"22","author":"Badiali","year":"2012","journal-title":"Brain Pathol"},{"key":"10.1016\/j.neurot.2026.e01050_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.681","article-title":"614MO type II RAF inhibitor tovorafenib in recurrent\/refractory (R\/R) melanoma or other solid tumors with RAF fusions and\/or RAF1 amplification","volume":"35","author":"Vieito","year":"2024","journal-title":"Ann Oncol"},{"issue":"7574","key":"10.1016\/j.neurot.2026.e01050_bib30","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14982","article-title":"RAF inhibitors that evade paradoxical MAPK pathway activation","volume":"526","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"16_suppl","key":"10.1016\/j.neurot.2026.e01050_bib31","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/JCO.2023.41.16_suppl.3006","article-title":"Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: results from a phase 1\/2a study","volume":"41","author":"De La Fuente","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01050_bib33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01050_bib34","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","article-title":"Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study","volume":"28","author":"Lassman","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.neurot.2026.e01050_bib35","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1200\/JCO.2025.43.16_suppl.2003","article-title":"A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: results from FIGHT-209","volume":"43","author":"Franceschi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.neurot.2026.e01050_bib36","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-14-2199","article-title":"Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma","volume":"21","author":"Di Stefano","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01050_bib37","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/neuonc\/noaa121","article-title":"Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions","volume":"22","author":"Di Stefano","year":"2020","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01050_bib38","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.ijrobp.2012.10.008","article-title":"RTOG 0211: a phase 1\/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients","volume":"85","author":"Chakravarti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01050_bib39","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","article-title":"Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034","volume":"27","author":"van den Bent","year":"2009","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.neurot.2026.e01050_bib40","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1200\/JCO.2008.18.0612","article-title":"Phase I\/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177","volume":"26","author":"Brown","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01050_bib41","first-page":"430","article-title":"Phase I\/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma","volume":"17","author":"Reardon","year":"2015","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01050_bib42","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.neurot.2026.e01050_bib43","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-14-3220","article-title":"A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01050_bib44","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","article-title":"A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma","volume":"51","author":"Westphal","year":"2015","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01050_bib45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/2159-8290.CD-11-0284","article-title":"Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors","volume":"2","author":"Vivanco","year":"2012","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01050_bib46","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","article-title":"Oncogene addiction","volume":"68","author":"Weinstein","year":"2008","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.neurot.2026.e01050_bib47","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa051918","article-title":"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors","volume":"353","author":"Mellinghoff","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01050_bib48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10637-015-0234-6","article-title":"A phase 1 study of ABT-806 in subjects with advanced solid tumors","volume":"33","author":"Cleary","year":"2015","journal-title":"Invest N Drugs"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01050_bib49","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/annonc\/mdp032","article-title":"Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma","volume":"20","author":"Neyns","year":"2009","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01050_bib50","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.10189","article-title":"Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene","volume":"98","author":"Johns","year":"2002","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01050_bib51","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/neuonc\/noz222","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume":"22","author":"Van Den Bent","year":"2020","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01050_bib52","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib53","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"issue":"19","key":"10.1016\/j.neurot.2026.e01050_bib54","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMc2201558","article-title":"Nivolumab with or without relatlimab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"Reply N Engl J Med"},{"issue":"13","key":"10.1016\/j.neurot.2026.e01050_bib55","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.neurot.2026.e01050_bib56","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-Cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.neurot.2026.e01050_bib57","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13Ralpha2-Redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01050_bib58","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"issue":"399","key":"10.1016\/j.neurot.2026.e01050_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.neurot.2026.e01050_bib60","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01050_bib61","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Ralpha2 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01050_bib62","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01050_bib63","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.neurot.2026.e01050_bib64","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01050_bib65","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e01050_bib66","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/B978-0-12-386509-0.00011-9","article-title":"Retroviral replicating vectors in cancer","volume":"507","author":"Logg","year":"2012","journal-title":"Methods Enzymol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01050_bib67","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/neuonc\/noy075","article-title":"Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC","volume":"20","author":"Cloughesy","year":"2018","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01050_bib68","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncol"},{"issue":"Supplement_8","key":"10.1016\/j.neurot.2026.e01050_bib69","doi-asserted-by":"crossref","first-page":"viii105","DOI":"10.1093\/neuonc\/noae165.0409","article-title":"CTNI-42. A biomarker-guided phase 2 study of DB107-RRV (a retroviral replicating vector) combined with DB107-FC (flucytosine extended-release tablets) in patients with recurrent glioblastoma or anaplastic astrocytoma: a clinical protocol","volume":"26","author":"Shah","year":"2024","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01050_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123721","article-title":"Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response","volume":"10","author":"Sesen","year":"2015","journal-title":"PLoS One"},{"issue":"40","key":"10.1016\/j.neurot.2026.e01050_bib71","doi-asserted-by":"crossref","first-page":"65643","DOI":"10.18632\/oncotarget.11595","article-title":"Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A)","volume":"7","author":"Choi","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01050_bib72","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10637-022-01277-9","article-title":"First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors","volume":"40","author":"Janku","year":"2022","journal-title":"Invest N Drugs"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib73","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01050_bib74","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ijc.32337","article-title":"Use of metformin and outcome of patients with newly diagnosed glioblastoma: pooled analysis","volume":"146","author":"Seliger","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.neurot.2026.e01050_bib75","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2018.05.005","article-title":"Brainstem blood brain barrier disruption using focused ultrasound: a demonstration of feasibility and enhanced doxorubicin delivery","volume":"281","author":"Alli","year":"2018","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01050_bib76","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1158\/0008-5472.CAN-12-2609","article-title":"Focused ultrasound delivers targeted immune cells to metastatic brain tumors","volume":"73","author":"Alkins","year":"2013","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01050_bib77","article-title":"Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01050_bib78","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijrobp.2020.12.019","article-title":"Focused ultrasound-mediated blood-brain barrier opening increases delivery and efficacy of etoposide for glioblastoma treatment","volume":"110","author":"Wei","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"615","key":"10.1016\/j.neurot.2026.e01050_bib79","doi-asserted-by":"crossref","first-page":"eabj4011","DOI":"10.1126\/scitranslmed.abj4011","article-title":"MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases","volume":"13","author":"Meng","year":"2021","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01050_bib80","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(25)00492-9","article-title":"Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1\/2 trial","volume":"26","author":"Woodworth","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib81","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41467-024-45818-7","article-title":"Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial","volume":"15","author":"Carpentier","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01050_bib82","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.ultrasmedbio.2022.12.006","article-title":"Molecular identity changes of tumor-associated macrophages and microglia after magnetic resonance imaging-guided focused ultrasound-induced blood-brain barrier opening in a mouse glioblastoma model","volume":"49","author":"Zhang","year":"2023","journal-title":"Ultrasound Med Biol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01050_bib83","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(22)00599-X","article-title":"Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial","volume":"23","author":"Spinazzi","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01050_bib84","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","article-title":"Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies","volume":"28","author":"van Putten","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neurot.2026.e01050_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.119088","article-title":"Targeting CSF1R: the development of small molecule inhibitors for cancer and other diseases","volume":"317","author":"Xia","year":"2026","journal-title":"Eur J Med Chem"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01050_bib86","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol Cancer Therapeut"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01050_bib87","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/nov245","article-title":"Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early phase clinical trials consortium phase II study","volume":"18","author":"Butowski","year":"2016","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01050_bib88","first-page":"vdae202","article-title":"Phase 1b\/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma","volume":"6","author":"Mendez","year":"2024","journal-title":"Neurooncol Adv"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01050_bib89","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01050_bib90","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1078-0432.CCR-24-1660","article-title":"Facts and hopes of CD40 agonists in cancer immunotherapy","volume":"31","author":"McVey","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01050_bib91","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41590-023-01430-3","article-title":"CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions","volume":"24","author":"Liu","year":"2023","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01050_bib92","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","article-title":"Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer","volume":"43","author":"Osorio","year":"2025","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01050_bib93","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Van Laethem","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neurot.2026.e01050_bib94","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-26-0655","article-title":"Pediatric brain tumor consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG","author":"Lindsay","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"7279","key":"10.1016\/j.neurot.2026.e01050_bib95","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature08712","article-title":"The transcriptional network for mesenchymal transformation of brain tumours","volume":"463","author":"Carro","year":"2010","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01050_bib96","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.immuni.2010.05.010","article-title":"Tumor-induced tolerance and immune suppression depend on the C\/EBPbeta transcription factor","volume":"32","author":"Marigo","year":"2010","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01050_bib97","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/1535-7163.MCT-21-0962","article-title":"Anticancer activity of ST101, A novel antagonist of CCAAT\/enhancer binding protein beta","volume":"21","author":"Darvishi","year":"2022","journal-title":"Mol Cancer Therapeut"},{"issue":"16_suppl","key":"10.1016\/j.neurot.2026.e01050_bib98","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1200\/JCO.2026.44.16_suppl.2079","article-title":"Lucicebtide (ST101) plus chemoradiation in newly diagnosed GBM patients: efficacy, pharmacodynamics, and safety from phase 2 window-of-opportunity study","volume":"44","author":"Iwamoto","year":"2026","journal-title":"J Clin Oncol"},{"issue":"7775","key":"10.1016\/j.neurot.2026.e01050_bib99","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","article-title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","volume":"573","author":"Venkataramani","year":"2019","journal-title":"Nature"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:53:56Z","timestamp":1792720436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926002205"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01050","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation therapeutics for glioblastoma: Challenges and future directions","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01050"}}